News
Pharmaceutical Technology on MSN4d
FDA awards breakthrough therapy status to BMS and SystImmune’s NSCLC drug
B ristol Myers Squibb and SystImmune have announced breakthrough therapy designation from the US Food and Drug Administration ...
The FDA granted breakthrough therapy designation to Ifinatamab deruxtecan for some with extensive-stage small cell lung ...
The FDA has awarded Breakthrough Therapy Designation to izalontamab brengitecan, a potential first-in-class bispecific ...
FDA designates ifinatamab deruxtecan as a breakthrough therapy for extensive-stage small cell lung cancer, promising improved ...
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to ifinatamab deruxtecan (I-DXd) for the treatment of adults with extensive-stage small cell lung cancer (ES-SCLC ...
Merck & Co (NYSE: MRK) and Daiichi Sankyo (TYO: 4568) have received Breakthrough Therapy designation from the US regulator ...
The Brighterside of News on MSN6d
Breakthrough laser therapy boosts memory recall by 25%
A simple beam of light may hold the power to sharpen your memory. New research shows that transcranial photobiomodulation, or ...
DYNE-251 received FDA breakthrough therapy designation, showcasing its potential for patients with Duchenne muscular ...
Developed by Daiichi Sankyo and Merck, it treats patients with Pretreated Extensive-Stage Small Cell Lung Cancer.
Recent advancements in Merck's (MRK) product portfolio, including the FDA's Breakthrough Therapy Designation for ifinatamab deruxtecan and several approvals of their flagship drug KEYTRUDA, are ...
Recently, Professor An Chiying and her medical team at Shenzhen Hengsheng Hospital, China, announced a groundbreaking ...
The FDA has granted Breakthrough Therapy designation to ifinatamab deruxtecan for the treatment of extensive-stage small cell lung cancer in pretreated patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback